....if all goes well.... planning to focus on influenza... and Inovio's unique value proposition..... Inovio could be an influenza-only focused company and have this market cap.... Lot's of work to deliver... but hope you like it when it appears.... Have to get it by the SA "Biotech Expert" who apparently has a bent against Inovio... LOL! He/she was "schooled" when the Roche deal was announced.... "priceless"!! BTW... just received my flu shot today.... wife says "I don't believe in it" so she didn't get it..... Hope to not be in the market for a new wife in a couple of years ;-)
"Biotech Expert" who apparently has a bent against Inovio..who is this person they have been very manipulative ? after emailing seeking alpha asking them a few questions about fraud when the last pure garbage untrue short article came out the same day the partnership was announced they have since relseaed 4 positive articles trying to cover their #$%$ it comedy to watch them try to clean up their mess
I would rather read how INO is a multi- faceted vaccine maker, not just a one trick pony vaccine. I like the fact that INO is letting Roshe earn the lion share of profits. Why is that? I think the reason is to not let just one company dominate the entire vaccine market, competition is good, creates better quality products, creates a market that is open to all that wish to pay Inovio the gate fees plus royalties to play. That is how INO will dominate the market. All vaccines will go through the Inovio gateway. Joe Kim is pushing big pharma's greed buttons... More big pharmas will line up for a lion share of the INO PIE... Money to be made over the long term. Profits will sky rocket after P3 and so will the gate fees .. Early in players get a discount to get the ball rolling. Many big pharmas are watching close. The gate fee to play, will increase much much more than ten million after phase 3. Joe Kim is like a great philharmonic conductor. Well orchestrated imo...
I Enjoy reading your SA articles.
Look forward to it Mark....The Influenza trial is one of the big three in Inovio's arsenal imo. There are 3 that are internally funded. 1) Cervical Dysplasia/Hpv now in Phase2 - VGX3100; 2) Influenza Universal - VGX3400x Phase 1 concluding; 3) Breast & Lung Cancer - Ino1400 ready to start Phase1..... This hTert Breast & Lung Cancer Therapeutic trial could be the biggest thing in their bag of tricks. A successful trial for breast cancer will put Inovio in the stratosphere as far as PPS & MC go. I hope they keep this in-house but fear they may partner this out like the prostate trials. The amount of press that would follow a promising breast cancer treatment would make Inovio a household name. Bigger than the influenza and the HPV indications imo....